Precision Medicine

A new blood test for Alzheimer's from Spear Bio wins a top tech award. Its unprecedented sensitivity could revolutionize early detection and treatment.

Quebec's funding for Roche's Itovebi offers new hope for breast cancer patients, but its complex approval reveals a national struggle over drug costs and access.

With 92% response rates in a deadly cancer and $1B in the bank, Tango Therapeutics is not just developing a drug—it's building a new industrial model for precision oncology.

A Fort Collins clinic is launching a program that merges psychiatry, functional medicine, and brain-mapping tech to treat co-occurring disorders. Is this the end of fragmented care?

Revenue missed and its stock plunged, but Quanterix is betting on a new C-suite and its Alzheimer's test to navigate market headwinds and deliver on its promise.

Health Canada's approval of Fasenra for HES marks a new era for patients. This is the story of how one drug intersects with patient hope and national policy.

A Utah biotech's new blood test can identify the exact brain cells dying in diseases like Alzheimer's, a major leap beyond today's diagnostics.

The University of New Mexico Comprehensive Cancer Center joins the Caris Precision Oncology Alliance, bringing advanced AI-driven diagnostics to the Southwest.

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

Zentalis Pharmaceuticals is pursuing a dual strategy for its ovarian cancer drug, azenosertib, aiming for fast market entry while securing long-term validation.

Breakthroughs in blood-based diagnostics are revolutionizing Alzheimer's care, but a new analysis reveals that compassionate communication is just as vital.

A historic $180M gift from The Sealy & Smith Foundation will transform UTMB's heart institute, funding state-of-the-art facilities and pioneering research.

Beyond the clinical data, ALX Oncology's latest update reveals a masterclass in strategic finance and leadership, positioning it for critical milestones.

With a new $345 genome and major clinical wins, PacBio pushes boundaries. But can its strategic restructuring and bold R&D overcome mounting financial losses?

Acrivon's ACR-2316 shows durable responses in lung cancer, moving to the next phase. The trial's design, guided by AI, aligns with new FDA standards.

Editas Medicine’s new board member signals a sharp focus on cardiovascular disease, a strategic pivot that could reshape the competitive gene editing race.

With a fortified balance sheet and a strategic pivot, OnKure Therapeutics is betting that precision and selectivity will conquer a competitive drug market.

A new partnership unites AI data-crunching with lab-grown human brain organoids, charting a bold roadmap to deconstruct Parkinson's into treatable subtypes.

In a strategic play, Archeus Technologies overhauls its advisory board, positioning itself to accelerate its cancer therapy pipeline in the booming RPT market.

Hidehiko Otake's promotion isn't just a corporate shuffle. It’s a bet that Corundum can turn our deepest biological data into the future of medicine.